A recombinant chimeric Ad5/3 vector expressing a multistage plasmodium antigen induces protective immunity in mice using heterologous prime-boost immunization regimens

Keyphrases

• Recombinant 100%
• Protective Immunity 100%
• Plasmodium 100%
• Heterologous Prime-boost 100%
• Immunization Regimen 100%
• Chimera 66%
• CD8+ T Cells 66%
• Protective Efficacy 66%
• Malaria Vaccine 66%
• Adenovirus 33%
• Safety Profile 33%
• High Prevalence 33%
• CD4+ T Cells 33%
• Linear Peptide 33%
• Immunization 33%
• Recombinant Protein 33%
• Chimeric Protein 33%
• Recombinant Viral Vectors 33%
• Immunology 33%
• Immunogenicity 33%
• Adenovirus Vector 33%
• Vaccine Candidate 33%
• Parasite Life Cycle 33%
• Vaccine Trial 33%
• Recombinant Adenovirus 33%
• Human Adenovirus Type 5 33%
• Plasmodium Yoelii 33%
• Yoelii 33%
• Neutralizing Abs 33%
• T Cell Epitope 33%
• Vaccine Platform 33%
• Autologous T Cell 33%
• Anti-disease 33%
• Protein Immunization 33%
• Pre-existing Immunity 33%
• Sporozoite 33%
• Circumsporozoite Protein 33%
• Single Immunization 33%
• Antiparasite 33%
• Partial Resistance 33%
• Malaria Vaccine Implementation Programme 33%
• Merozoite Surface Protein 33%
• Memory Profiling 33%
• Pre-erythrocytic Vaccine 33%

Immunology and Microbiology

• Cytotoxic T-Cell 100%
• Plasmodium 100%
• Adenovirus Vector 100%
• Prevalence 50%
• T Cell 50%
• T-Helper Cell 50%
• Life Cycle 50%
• Epitope 50%
• Adenoviridae 50%
• Immunology 50%
• Immunogenicity 50%
• Viral Vector 50%
• Human Adenovirus 5 50%
• Plasmodium yoelii 50%
• Circumsporozoite Protein 50%
• Sporozoite 50%
• Merozoite Surface Protein 1 50%
• Peptides 50%